Title:
MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
Document Type and Number:
WIPO Patent Application WO/2023/131098
Kind Code:
A3
Abstract:
Provided is a chimeric antisense compound comprising a modified oligonucleotide comprising 5' W1-G1-S1-G2-W2 3', wherein: W1 is a 5' wing segment, W2 is a 3' wing segment, G1 is a first gap segment, S1 is a first separator segment, and G2 is a second gap segment. Also provided is a method for decreasing HBV mRNA, DNA and protein expression. Such compounds and methods are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.
Inventors:
CHENG GUOFENG (US)
YANG CHENG YONG (US)
YANG CHENG YONG (US)
Application Number:
PCT/CN2023/000030
Publication Date:
September 21, 2023
Filing Date:
January 10, 2023
Export Citation:
Assignee:
AUSPER BIOPHARMA CO LTD (CN)
International Classes:
C12N15/113; A61K31/7115; A61P31/20; C07H21/00
Domestic Patent References:
| WO2012145697A1 | 2012-10-26 |
Foreign References:
| CN113573730A | 2021-10-29 | |||
| US20170145424A1 | 2017-05-25 | |||
| US20120295961A1 | 2012-11-22 |
Other References:
XIAOYING ZHU ET AL.: "The difference of anti-virus effect between different modified antisense oligonucleotides in vitro", ZHONGHUA GANZANGBING ZAZHI - CHINESE JOURNAL OF HEPATOLOGY, CHONGQING, CN, vol. 21, no. 6, 30 June 2013 (2013-06-30), CN , pages 475 - 476, XP009549108, ISSN: 1007-3418
YUEN MAN-FUNG; HEO JEONG; JANG JEONG-WON; YOON JUNG-HWAN; KWEON YOUNG-OH; PARK SUNG-JAE; TAMI YVONNE; YOU SHIHYUN; YATES PHILLIP; : "Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial", NATURE MEDICINE, NATURE PUBLISHING GROUP US, NEW YORK, vol. 27, no. 10, 1 October 2021 (2021-10-01), New York, pages 1725 - 1734, XP037589817, ISSN: 1078-8956, DOI: 10.1038/s41591-021-01513-4
YUEN MAN-FUNG; HEO JEONG; JANG JEONG-WON; YOON JUNG-HWAN; KWEON YOUNG-OH; PARK SUNG-JAE; TAMI YVONNE; YOU SHIHYUN; YATES PHILLIP; : "Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial", NATURE MEDICINE, NATURE PUBLISHING GROUP US, NEW YORK, vol. 27, no. 10, 1 October 2021 (2021-10-01), New York, pages 1725 - 1734, XP037589817, ISSN: 1078-8956, DOI: 10.1038/s41591-021-01513-4
Attorney, Agent or Firm:
WU, FENG & ZHANG (CN)
Download PDF: